ClinicalTrials.gg
CompletedNCT04179669Updated Aug 9, 2023

Safety and Efficacy of IBI306 in HeFH Patients

A Phase 3 interventional study of IBI306 and placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 14 under way, 8 of them phase 3. Hyperlipoproteinemia Type II · China.

Enrollment
11th of 22
149 · median 142
Started
2019
with 1 other
Phase 3
13 of 24
6 open now
Registered
3rd of 24
by date
Lead sponsor
2 of 24
Innovent Biologics (Suzhou) Co. Ltd.

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 11th largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2019, is one of 13 in phase 3, and was the 3rd registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

IBI306 is a fully human monoclonal antibody that binds proprotein convertase substilisin/kexin type 9 (PCSK-9), preventing its interaction with the low-density lipoprotein cholesterol receptor (LDL-R) and thereby restoring LDL-R recycling and low-density lipoprotein cholesterol (LDL-C) uptake. In the phase I study, IBI306 was shown to be safe and well tolerated. There was robust reduction in LDL-C, Apo(B), non-HDL-C and lipoprotein (a) in healthy subjects. This study is a randomized, double-blind, placebo-controlled, repeated-dosing, multiple ascending dose trial to evaluate the efficacy and safety of a novel PCSK-9 anti-body, IBI306, in Chinese patients with heterozygous familial hypercholesterolemia.

Read the detailed description

The study plans to enroll 148 patients with heterozygous familial hypercholesterolemia. Subjects will maintain a low-fat diet and stable current lipid-lowering therapy for at least 4 weeks and will be randomized into different dose groups at a 1:1 ratio, followed by a 2:1 randomization double-blind treatment with subcutaneous IBI306 150 mg (n=49) or placebo (n=25) every two weeks; or subcutaneous injection of IBI306 450mg (n=49) or placebo (n=25) every four weeks. Treatment lasts for 12 weeks. After 12 weeks, each group enters a 12-week open-label treatment, in which IBI306 subjects continue to receive IBI306, and placebo subjects shift to receive IBI306. The primary endpoint is the percent change in LDL-C levels relative to baseline at 12 weeks. Secondary endpoints include changes in baseline lipid levels, drug safety, and immunogenicity at 12 weeks and 24 weeks. The exploratory endpoint is the population pharmacokinetic profile of IBI306 in Chinese subjects with heterozygous familial hypercholesterolemia. If necessary, the dose of IBI306 will be adjusted accordingly based on the results of the ongoing multi-dose escalation study. After the open period, the subjects will be given a safety visit for 8 weeks.

03

Conditions studied

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following inclusion criteria in order to be included in the study:
  • Provide a signed and dated form
  • Men or women 18 to 70 years of age at screening
  • Weight ≥ 40 kg during screening
  • Confirmed diagnosis of heterozygous familial hypercholesterolemia
  • Maintain a low-fat diet and stabilize the current lipid-lowering therapy

Exclusion criteria

Exclusion Criteria:

  • Subjects who do not meet any of the following exclusion criteria cannot be included in the study:
  • Patients diagnosed as homozygous familial hypercholesterolemia
  • Dialysis or plasmapheresis performed within 4 months prior to screening
  • History of liver transplant
  • Subjects adjusted for treatment of statins, ezetimibe, niacin, omega-fatty acids within 4 weeks prior to screening
  • (NYHA) grade III or IV heart failure, or recent detection of ≤ 30%
  • Have serious cardiovascular, cerebrovascular, liver and kidney related diseases
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
149 participants (actual)

Study arms

  • Experimental
    IBI306

    Participants received IBI306 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.

    Drug: IBI306

  • Experimental
    placebo

    Participants received Placebo 150 mg subcutaneously Q2W or 450mg Q4W for 12 weeks.

    Drug: placebo

Interventions

  • DrugIBI306

    Administered by subcutaneous injection

  • Drugplacebo

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage of LDL-C decreased from baseline injection.

    Time frame: at 12 weeks

Secondary outcomes

  1. Percentage change of LDL-C from baseline

    Time frame: to 24 weeks

  2. Changes in LDL-C levels relative to baselin

    Time frame: at 12 and 24 weeks

  3. The proportion of patients with LDL-C that were 50% lower than baseline

    Time frame: by 12 weeks and 24 weeks

07

Study locations

1 site
  • Beijing Anzhen Hospital, Capital Medical University
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Jun 2021, 18 months.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's 18 months is below that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2019
First posted
Nov 27, 2019
StartActual
Dec 20, 2019
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Last update
Aug 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04179669
Responsible party
Sponsor
First posted
Nov 27, 2019
Start date
Dec 20, 2019
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Aug 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion